	US 12,128,040 B2
	Selective estrogen receptor degraders
Jeffrey Daniel Cohen, Indianapolis, IN (US); and Daniel Jon Sall, Greenwood, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Appl. No. 17/254,991
Filed by Eli Lilly and Company, Indianapolis, IN (US)
PCT Filed Jul. 11, 2019, PCT No. PCT/US2019/041342 § 371(c)(1), (2) Date Dec. 22, 2020, PCT Pub. No. WO2020/014440, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/825,172, filed on Mar. 28, 2019.
Claims priority of provisional application 62/697,100, filed on Jul. 12, 2018.
Prior Publication US 2021/0260052 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01)

CPC A61K 31/4709 (2013.01) [A61K 9/0053 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01)]

7 Claims

1. A compound of the formula

or a pharmaceutically acceptable salt thereof.